Phase 3 Clinical Trial of Teriparatide in Japan

Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis

To evaluate the efficacy of teriparatide based on measurements of bone mineral density at lumbar spine

Inclusion Criteria:

• Japanese patients diagnosed with osteoporosis
• Aged 55 or older
• Patients who are at high risk for fracture

Exclusion Criteria:

• History of metabolic bone disorders other than primary osteoporosis
• History of malignant neoplasm in the 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated.
• Severe or chronically disabling conditions other than osteoporosis